Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Could Moderna/Merck Cancer Vaccine Succeed Where Others Have Flopped?

Executive Summary

The partners unveiled long-awaited proof-of-concept data for mRNA-4157 at the AACR meeting showing a statistically significant improvement in recurrence-free survival among melanoma patients.

You may also be interested in...



Moderna Shows Ambition With Flu Success And Cancer Therapy Expansion

Slower COVID-19 vaccine sales will see Moderna’s revenues decline this year, but the company is investing heavily to speed a new wave of therapies to the market.

Moderna and CARsgen Look For Synergies In CAR-T And Cancer Vaccine Combo

While Astellas is closing in on the first Claudin18.2 antibody therapy cancer approval, CARsgen and Moderna aim to boost responses from a CAR-T approach.

Rise In COVID-19 Numbers Won’t Solve Moderna’s Slump

Moderna is suffering from a slump in sales of its COVID-19 vaccine, and investors remain skeptical about its chances of hitting anywhere near those blockbuster heights with its next wave of products.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC148215

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel